EYENOVIA INC. - COMMON STOCK

Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue

15 Jun 2021 07:00:02 By Nasdaq GlobeNewswire

Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia

25 May 2021 08:03:54 By Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2021 Financial Results

12 May 2021 15:05:01 By Nasdaq GlobeNewswire

Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank

10 May 2021 07:30:00 By Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12

05 May 2021 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results

25 Mar 2021 15:05:00 By Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25

18 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Participate in the 33rd Annual Roth Conference

10 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Eyenovia to Host Key Opinion Leader Webinar on Presbyopia

16 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event

06 Jan 2021 07:00:01 By Nasdaq GlobeNewswire